Immix Biopharma prices $150M public offering of 16.8M shares at $8.94

Immix Biopharma, Inc.

Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.
Offering of 16,778,524 shares priced at $8.94 per share; closes May 22, 2026.
Net proceeds to fund NXC-201 development, working capital, and general corporate purposes.
Cash runway extended to mid-2028 with existing cash plus offering net proceeds.
Morgan Stanley leads underwriters; BofA Securities, LifeSci Capital, Mizuho, Needham co-manage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.